Doctor-manufacturer deals under scrutiny after drug settlement
Providers will see heightened scrutiny of their relationships with pharmaceutical and medical device manufacturers in light of one of the largest health care fraud settlements in history. Johnson & Johnson (J&J) agreed to pay $2.2 billion in civil and criminal penalties and the government is cracking down.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.